ArticleAmerican journal of translational research2026
Clinical efficacy and gastrointestinal hormonal effect of
Article in American journal of translational research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThis study aimed to explore the clinical efficacy of
methodsA prospective, randomized, double-blind trial was conducted with three groups: control (n=45, mosapride citrate tablets), monotherapy (n=44, lactulose + control regimen), and combination (n=45, Lactobacillus rhamnosus + monotherapy regimen). The primary outcome measure was clinical efficacy. Secondary outcomes included the Bristol Stool Scale (BSS), Irritable Bowel Syndrome Quality of Life Score (IBS-QoL), Perceived Stress Scale (PSS), Irritable Bowel Syndrome Severity Score (IBS-SSS), gut microbiota, and gastrointestinal hormones assessed at days 0, 28, and 56, along with safety observations.
resultsFollowing a 56-day intervention period, the combination group achieved 100.00% clinical effectiveness, significantly higher than the monotherapy (93.18%) or control groups (75.56%). Fecal consistency responders were 84.44% in the combination group vs. 47.73% (monotherapy) and 28.89% (control). The combination group showed higher IBS-QoL scores, lower PSS scores, and reduced IBS-SSS scores (
conclusion
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.